LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

Home・Aktien・Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals Inc

Geschlossen

BrancheGesundheitswesen

628.61 1.61

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

618.69

Max

631.75

Schlüsselkennzahlen
By Trading Economics
Einkommen	-117M 727M
Verkäufe	-279M 3.6B
KGV Branchendurchschnitt	14.661 49.888
EPS	9.47
Dividendenrendite	0.58
Gewinnspanne	20.17
Angestellte	15,343
EBITDA	-234M 967M

Empfehlungen
By TipRanks
Empfehlungen	Buy
12-Monats-Prognose	+34.06% upside

Dividenden
By Dow Jones
Dividendenrendite Branchendurchschnitt	0.58% 2.38%
Nächstes Ergebnis	31. Juli 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-15B 63B
Vorheriger Eröffnungskurs	627
Vorheriger Schlusskurs	628.61

Nachrichtenstimmung

By Acuity

41%

59%

132 / 344 Ranking in Healthcare

Regeneron Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Peer-Vergleich

Kursveränderung

Regeneron Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

34.06% Vorteil

12-Monats-Prognose

Durchschnitt 829.77 USD 34.06%

Hoch 995 USD

Tief 641 USD

Basierend auf 22 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Regeneron Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

22 ratings

Buy

Halten

Sell

Basierend auf 22 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Regeneron Pharmaceuticals Inc – Dist abgegeben haben.

Stimmung

By Acuity

132 / 344 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.